CRISPR vs cancer: The double-edged sword of efficiency

CRISPR vs Cancer: The Double-edged Sword of Efficiency

QKPFX1 The oversimplification trap behind QK precision medicine

90% of patients with advanced cancer ask the same question: "Can gene editing be used? "At the same time, 90% of CRISPR anti-cancer therapies are stuck in clinical phase II. This numerical difference is not a technical bottleneck, but a critical hit of biological complexity on efficiency.

1. Has the "non-drug" target been breached? Look at the price first

The KRAS mutation, the "death penalty notice" for lung cancer, was finally locked in by CRISPR therapy [NT-113] last year. What the press release said was "Accurately cutting off mutant genes", but what it didn't say was:
The - delivery system uses an adenovirus vector, and the patient's bone marrow must be cleared with chemotherapy before implantation

• Mis-target rate 7.3%([Nature 2023]), which is equivalent to accidentally injuring 1 healthy cell for every 14 cancer cells cut
• Treatment cost : A single injection of US$470,000, enough for 78 traditional radiotherapy

Bioengineers like to say "it's like fixing a code bug," but the human body doesn't have a git reset --hard*. After the cancer cells are cut off, fibroblasts in the microenvironment immediately secrete [IL-11] to rebuild the tumor niche-equivalent to deleting malicious programs, but the system automatically reinstalls the virus.

2. The temptation and backlash of efficiency

The promise of precision medicine : Find carcinogenic targets → design gRNA→ cure with one injection. Realistic path : Find the target → Find the target to mutate → Design 10 sets of gRNAs → The patient has metastasized.

The 2023 MD Anderson Cancer Center trial reveals something even more absurd:

1. attacks solid tumors with CRISPR-edited T cells
2. Tumor shrank by 40% after 3 months
3. Cancer cells turn on "stealth mode" in month 4 : down-regulate MHC-I expression (immune system recognition switch)
4. immune cells cannot find their target and start attacking the liver

"We are not treating diseases, we are playing a game against 3.8 billion years of evolution. "
-Private comment by the chief scientific officer of a gene therapy company

This is interesting: When technology uses "efficiency" to kidnap decisions, patients turn from people to data points .

• doctors dare not say "observe for another half a year" for fear of being complained and giving up treatment
• investors require 18 months to release clinical data
• media title will always be a "major breakthrough"

3. Tears of Lao Zhang and patients in the Oncology Department

Lao Zhang always has three boxes of tissue in his clinic. Last week, a patient with terminal gastric cancer knelt and begged him: "Professor, I also want to do gene therapy to sell the house. The news said that it can be eradicated! "

Lao Zhang opened the literature page on his computer: [Science 2024] Statistics 217 cases of CRISPR solid tumors were treated, and the 12-month recurrence rate was 91%. He looked at the firefly-like metastases on the CT scan and knew that the $500,000 injection injection would most likely just tickle the cancer cells.

"Use the plan that can be reimbursed by medical insurance first, and see the effect after three months? "He suggested. The patient's family slammed the door and walked out: "You just want to get kickbacks! "

The electronic screen outside the door is rolling with the happy news of "Gene editing cures the first lung cancer patient." No one told those waiting: the "cured" patient, clinical trial number CA-1024, died of bone marrow suppression six months later.

-When medical care becomes an arms race, rational decision-making becomes a luxury

4. Commercial accounts: Who is paying for "precision"?

There are three key sets of figures in CRISPR therapy development:

1. 10 years : Average R & D cycle (6.5 years for traditional anticancer drugs)
2. US$2.6 billion : Cost to market for a single product
3. <1%: Proportion of applicable patients

Pharmaceutical companies certainly know how to calculate accounts: Betting on rare diseases is more cost-effective than conquering lung cancer .

• Editor Retinal cells for the treatment of genetic eye diseases: 20,000 patients, priced at US$2 million, are still paid for by medical insurance
• Editor T cell treatment of pancreatic cancer: 500,000 patients, price of 500,000 was refused insurance

Venture Capital is more realistic: "We invest in platform technology, whether it treats cancer or hair loss! "So CRSPR companies transformed one after another:

• Editas cuts 50% of tumor pipelines
• Intellia focuses on liver disease
• Anti-cancer has become a technology booth, treating diseases is just a passing pass

5. Don't get me wrong, I'm not scolding technology

CRISPR is certainly valuable, but when it is packaged as a silver anti-cancer bullet, it becomes a gun pointed at the patient .

What should really be wary of is this narrative:

1. Create false hope → Patients abandon more cost-effective treatment options
2. Covers System Complexity → Funding Flows to "Gene Editing" Tag Project
3. Distorts medical resources → Top A hospitals compete to build gene centers, but community hospitals 'chemotherapy departments are short of drugs

To put it counter-intuitively: When CAR-T therapy was first launched, it promoted "clearing cancer cells with one dose." Now clinical guidelines require that it must be combined with radiotherapy to reduce tumor burden -After the myth of efficiency is shattered, the focus is still comprehensive medical capabilities.

QKPFX30 The ultimate price of QK efficiencism: depriving humans of their dignity in the face of death

The most magical scene takes place in the gene therapy consultation room:
The patient held the Nature paper and asked: "Can I edit my P53 gene to prevent recurrence? "
The doctor sighed: "Do you know that P53 is still responsible for DNA repair? Cutting the wrong place may induce new cancer... "
Family members patted the table: "You just don't have skills! "

When we use the words "repair","precision" and "one-click removal" to describe the war on cancer, we are essentially denying the chaotic nature of living systems- Cancer is a by-product of evolution, and evolution never accepts Ctrl+Z.

There is a note posted next to Lao Zhang's computer, which comes from an academic conference:

"Sometimes healing, often helping, always comforting"
In the CRISPR era, this sentence needs to be annotated:
"Never Promise"*